Roche Presents Positive Preclinical Data On Genmab Antibody
The fully human IgG1,k antibody, called R1507, which is in Phase I clinical development, was selected from a large panel of antibodies and was found to be very good at binding to its target, the Insulin-like Growth factor-1 Receptor (IGF-1R). R1507 was shown to block binding of IGF-1 and IGF-2, and to potently inhibit IGF-1R signaling. In addition, R1507 was found to effectively stop tumor cell growth in different animal models.
The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed. IGF-1R is over-expressed on a variety of tumors including breast, colon, prostate, lung, skin and pancreatic cancers and is a well validated target for an antibody therapeutic approach.
These data make R1507 a promising antibody for further evaluation in clinical trials and development of a novel immunotherapeutic approach for treatment of cancers that over-express IGF-1R.
"This is the first data presented on one of the antibodies produced in our collaboration with Roche," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We are pleased with the positive preclinical results which highlight the prospects of R1507 as a clinical program."
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has developed UniBody(TM), a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, Princeton, New Jersey, US and Hertfordshire in the United Kingdom. For more information about Genmab, visit http://www.genmab.com.
This press release contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax- EGFr(TM); HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM); and UniBody(TM) are all trademarks of Genmab A/S. UltiMAb(R) is a trademark of Medarex, Inc.
Genmab A/S
http://www.genmab.com
Roche a prezentat pozitiv disponibile date preclinice despre Genmab anticorp - Roche Presents Positive Preclinical Data On Genmab Antibody - articole medicale engleza - startsanatate